Mural Oncology reports Q2 net loss $48M; exploring strategic alternatives after pipeline discontinuation

Mural Oncology plc

2025-Q2 EPS reported -$4.71

Net loss of $48.0M for Q2 2025, compared to $31.6M in Q2 2024, driven by $17.5M restructuring and impairment charges.
Workforce reduced by ~90%; discontinued all clinical development of nemvaleukin alfa and terminated IL-18 and IL-12 programs.
Cash and equivalents $77.1M at June 30, 2025; projected $43–48M by Dec 31, 2025 if no strategic transaction completed.
R&D expenses fell to $23.3M from $27.5M; G&A rose to $8.1M from $6.7M due to severance, retention, and legal costs.
Exploring strategic alternatives, including possible wind-down and liquidation; no assurance of any transaction.

item 2.02item 9.01

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.